Shares of Boston Scientific Corp. rose 1.7% in premarket trade Thursday, after the company said the U.S. Food and Drug Administration has approved its Spectra WaveWriter spinal cord simulator system, a non-opioid treatment for chronic pain. “It is the first and only system approved by the FDA to simultaneously provide paresthesia-based and sub-perception therapy,” the company said in a statement. The system sends low electrical pulses to the spinal cord to interrupt pain signals. “Paresthesia-based therapy provides pain relief with a light tingling sensation while sub-perception therapy works without that sensation,” said the statement. Patients can combine therapies to best manage multiple areas of pain. More than 100 million Americans suffer from chronic pain, which is the leading cause of disability in adults. Shares have gained 18% in the last 12 months, while the S&P 500 has gained 21%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News